ElexoPharm GmbH Receives ETB Grant
News Oct 18, 2012
Recently, a EuroTransBio grant of €1.5 million has been awarded to a transnational consortium including ElexoPharm GmbH by the European Collaborative ETB program.
The project is a collaboration of ElexoPharm GmbH with SomantiX BV (Bilthoven, The Netherlands), VU University Medical Center (Amsterdam, The Netherlands), Saarland University (Saarbrücken, Germany) and PharmBioTec GmbH (Saarbrücken, Germany).
This subsidy is awarded for a period of three years and will allow the development of low molecular weight inhibitors of angiogenesis in colorectal cancer.
At ElexoPharm, lead finding and lead optimization based on molecular modelling, design and synthesis of biological active compounds, will be performed.
"ElexoPharm is very proud to have received this prestigious transnational grant to develop medicines to treat this disease of high medical need. It is a further recognition of the excellent drug discovery capabilities of our growing company", states Axel Koch, Managing Director of ElexoPharm.
Cells Missing Nuclei Struggle to Move in 3D EnvironmentsNews
University of North Carolina Lineberger Comprehensive Cancer Center researchers have revealed new details of how the physical properties of the nucleus influence how cells can move around different environments.READ MORE
Cancer Stem Cell Survival is Controlled by Hedgehog Signaling ProteinsNews
Research reveals that cancer stem cell survival is controlled by a specific feature of the Hedgehog signaling pathway (SHH-PTCH1), which allows cells to respond to external signals in addition to inhibiting stem cell differentiation.READ MORE
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE